{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:45:20Z","timestamp":1787071520848,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>The purpose of the study was to measure serum angiotensin-converting enzyme (ACE) in patients diagnosed with idiopathic and demyelinating optic neuritis (ON) as well as heathy individuals and assess its viability as a biomarker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>This clinical case\u2013control study was conducted on patients diagnosed with acute ON as the case group and healthy controls aged between 18 and 50 years. Based on findings from systemic and neurological evaluation, the study group was divided into: Idiopathic ON and demyelinating ON (including multiple sclerosis [MS], neuromyelitis optica [NMO], and clinically isolated syndrome [CIS]) subgroups. Serum ACE levels were measured using enzyme-linked immunosorbent assay and compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Fifty-one patients with acute ON (78.4% female, mean age 29.8 \u00b1 8.4 years) and 51 controls (78.4% female, mean age 29.9 \u00b1 6.9 years) were enrolled in this study. In the case group, 29 patients were diagnosed with idiopathic ON (56.9%), and 22 patients with demyelinating types of ON (43.1%) (MS-ON,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 16; NMO-ON,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 3; and CIS,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 3). The median serum ACE levels were 33.50 U\/L (range: 29.40\u201346.20), and 34.25 U\/L (range: 29.30\u201346.10) for patients diagnosed with idiopathic ON and demyelinating ON, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.99). The mean serum ACE level for healthy individuals was 26.2 U\/L (range: 24.80\u201320.50), and compared to other groups, it was significantly different (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Abnormal levels of serum ACE (defined as a serum ACE &gt;65 U\/L) were measured in 3 (10.3%) patients with idiopathic ON and 2 (9.1%) patients with the demyelinating ON (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.99).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Our findings did not exhibit a significant difference in terms of serum ACE level between patients diagnosed with idiopathic ON and demyelinating ON. However, serum ACE level in both groups is significantly higher compared to healthy subjects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjopt.sjopt_118_24","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T08:00:09Z","timestamp":1753430409000},"page":"378-382","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Is serum angiotensin-converting enzyme a suitable biomarker for differentiating idiopathic and demyelinating optic neuritis?"],"prefix":"10.4103","volume":"39","author":[{"given":"Alireza","family":"Dehghani","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran-Sadat","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Mirmohammadkhani","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Irajpour","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Moayeri","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Amirkhani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Esfahanian","sequence":"additional","affiliation":[{"name":"Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Pourazizi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"R1-20251201","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3988\/jcn.2018.14.3.351","article-title":"Recurrent optic neuritis as the initial symptom in demyelinating diseases","volume":"14","author":"Falc\u00e3o-Gon\u00e7alves","year":"2018","journal-title":"J Clin Neurol"},{"key":"R2-20251201","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol"},{"key":"R3-20251201","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.survophthal.2019.06.001","article-title":"Critical review: Typical and atypical optic neuritis","volume":"64","author":"Abel","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"R4-20251201","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.survophthal.2019.08.001","article-title":"Optic neuritis in the era of biomarkers","volume":"65","author":"Chen","year":"2020","journal-title":"Surv Ophthalmol"},{"key":"R5-20251201","first-page":"727","article-title":"Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up","volume":"65","author":"Brodsky","year":"2008","journal-title":"Arch Neurol"},{"key":"R6-20251201","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/jnnp-2022-330608","article-title":"Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders","volume":"94","author":"Oertel","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R7-20251201","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/jnnp-2021-327412","article-title":"Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders","volume":"93","author":"Lu","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R8-20251201","doi-asserted-by":"crossref","first-page":"e1068","DOI":"10.1212\/NXI.0000000000001068","article-title":"Retinal optical coherence tomography in neuromyelitis optica","volume":"8","author":"Oertel","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R9-20251201","doi-asserted-by":"crossref","first-page":"e035397","DOI":"10.1136\/bmjopen-2019-035397","article-title":"Cohort profile: A collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO)","volume":"10","author":"Specovius","year":"2020","journal-title":"BMJ Open"},{"key":"R10-20251201","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3390\/ijms19030876","article-title":"Within the brain: The renin angiotensin system","volume":"19","author":"Jackson","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R11-20251201","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ggi.13927","article-title":"Effect of renin-angiotensin system on senescence","volume":"20","author":"Mogi","year":"2020","journal-title":"Geriatr Gerontol Int"},{"key":"R12-20251201","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.sjbs.2020.01.026","article-title":"Role of brain renin angiotensin system in neurodegeneration: An update","volume":"27","author":"Abiodun","year":"2020","journal-title":"Saudi J Biol Sci"},{"key":"R13-20251201","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.ajpath.2017.08.012","article-title":"The renin-angiotensin system regulates neurodegeneration in a mouse model of optic neuritis","volume":"187","author":"Guo","year":"2017","journal-title":"Am J Pathol"},{"key":"R14-20251201","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11481-019-09894-7","article-title":"Activation of the protective arm of the renin angiotensin system in demyelinating disease","volume":"15","author":"Stone","year":"2020","journal-title":"J Neuroimmune Pharmacol"},{"key":"R15-20251201","doi-asserted-by":"crossref","first-page":"1470320316666750","DOI":"10.1177\/1470320316666750","article-title":"Renin-angiotensin system gene expression and neurodegenerative diseases","volume":"17","author":"Goldstein","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R16-20251201","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fnagi.2017.00129","article-title":"Brain renin-angiotensin system and microglial polarization: Implications for aging and neurodegeneration","volume":"9","author":"Labandeira-Garcia","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"R17-20251201","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jns.2010.05.014","article-title":"CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity","volume":"295","author":"Matsushita","year":"2010","journal-title":"J Neurol Sci"},{"key":"R18-20251201","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jns.2016.02.026","article-title":"Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis","volume":"363","author":"\u017divkovi\u0107","year":"2016","journal-title":"J Neurol Sci"},{"key":"R19-20251201","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00281-020-00819-8","article-title":"Involvement of dopaminergic signaling in the cross talk between the renin-angiotensin system and inflammation","volume":"42","author":"Campos","year":"2020","journal-title":"Semin Immunopathol"},{"key":"R20-20251201","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11062-019-09760-5","article-title":"Serum angiotensin-converting enzyme in patients suffering from multiple sclerosis and healthy controls: A pilot study","volume":"50","author":"Razazian","year":"2018","journal-title":"Neurophysiology"},{"key":"R21-20251201","first-page":"4867420","article-title":"Serum Level of the Angiotensin-Converting Enzyme in Patients with Idiopathic Acute Optic Neuritis: A Case-Control Study","author":"Ghanbari","year":"2020","journal-title":"Scientifica (Cairo) 2020"},{"key":"R22-20251201","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/acn3.51070","article-title":"Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases","volume":"7","author":"Lee","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"R23-20251201","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12974-019-1440-5","article-title":"Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: A population-based prospective cohort study","volume":"16","author":"Olesen","year":"2019","journal-title":"J Neuroinflammation"},{"key":"R24-20251201","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2","author":"Melamed","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R25-20251201","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/1352458519860327","article-title":"Angiotensin AT2 receptor-induced interleukin-10 attenuates neuromyelitis optica spectrum disorder-like pathology","volume":"26","author":"Khorooshi","year":"2020","journal-title":"Mult Scler"},{"key":"R26-20251201","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"R27-20251201","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1352458508097923","article-title":"Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis","volume":"15","author":"Kawajiri","year":"2009","journal-title":"Mult Scler"}],"container-title":["Saudi Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjopt.sjopt_118_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:47:23Z","timestamp":1787068043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjopt.sjopt_118_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/sjopt.sjopt_118_24","relation":{},"ISSN":["1319-4534","2542-6680"],"issn-type":[{"value":"1319-4534","type":"print"},{"value":"2542-6680","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"2024-05-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}